Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume 6, Issue 10, Pages 995-1025
Publisher
Informa Healthcare
Online
2011-09-03
DOI
10.1517/17460441.2011.608063
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of blockage of the endocannabinoid system by CB1 antagonism on cardiovascular risk
- (2014) François Mach et al. Pharmacological Reports
- Blockade of the Cannabinoid CB1 Receptor and Alcohol Dependence: Preclinical Evidence and Preliminary Clinical Data
- (2012) Paola Maccioni et al. CNS & Neurological Disorders-Drug Targets
- Binding between a Distal C-Terminus Fragment of Cannabinoid Receptor 1 and Arrestin-2
- (2011) Shubhadra N. Singh et al. BIOCHEMISTRY
- The case for peripheral CB1receptor blockade in the treatment of visceral obesity and its cardiometabolic complications
- (2011) George Kunos et al. BRITISH JOURNAL OF PHARMACOLOGY
- Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
- (2011) E L Karschner et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A New Perspective of Cannabinoid 1 Receptor Antagonists: Approaches Toward Peripheral CB1R Blockers without Crossing the Blood-Brain Barrier
- (2011) Yen-Ku Wu et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis
- (2011) J. D. O'Hare et al. DIABETES
- Cannabinoids Inhibit Insulin Receptor Signaling in Pancreatic -Cells
- (2011) W. Kim et al. DIABETES
- Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity
- (2011) A. Quercioli et al. EUROPEAN HEART JOURNAL
- The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆9-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice
- (2011) D. Matthew Walentiny et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial
- (2011) D. H. O'Leary et al. HEART
- National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants
- (2011) Mariel M Finucane et al. LANCET
- Phase III and submission failures: 2007–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral-Antagonist/Inverse-Agonist Therapies
- (2011) Sara Jane Ward et al. Obesity
- Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats
- (2011) Torbjörn U. C. Järbe et al. PSYCHOPHARMACOLOGY
- HIV protease inhibitors and obesity
- (2011) Erdembileg Anuurad et al. Current Opinion in Endocrinology Diabetes and Obesity
- Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use
- (2010) A. K. B. Van Reedt Dortland et al. ACTA PSYCHIATRICA SCANDINAVICA
- Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype
- (2010) Galina Burdyga et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Rodent models in depression research: Classical strategies and new directions
- (2010) Daniela D. Pollak et al. ANNALS OF MEDICINE
- The Endocannabinoid System and Its Relevance for Nutrition
- (2010) Mauro Maccarrone et al. Annual Review of Nutrition
- Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
- (2010) Dina G. Tiniakos et al. Annual Review of Pathology-Mechanisms of Disease
- Overweight, Obesity, and Depression
- (2010) Floriana S. Luppino et al. ARCHIVES OF GENERAL PSYCHIATRY
- Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice
- (2010) Paolo Lazzari et al. BEHAVIOURAL BRAIN RESEARCH
- Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1receptor blockade
- (2010) Ana Crespillo et al. BIOCHEMICAL JOURNAL
- Functionally selective cannabinoid receptor signalling: Therapeutic implications and opportunities
- (2010) Barbara Bosier et al. BIOCHEMICAL PHARMACOLOGY
- Obesity as a clinical and public health problem: Is there a need for a new definition based on lipotoxicity effects?
- (2010) Thorkild I.A. Sørensen et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif
- (2010) Laurent Hortala et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation. Part 1
- (2010) John S. Debenham et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: Synthesis, SAR and biological evaluation
- (2010) Christina B. Madsen-Duggan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats
- (2010) CL Limebeer et al. BRITISH JOURNAL OF PHARMACOLOGY
- A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents
- (2010) NL Cluny et al. BRITISH JOURNAL OF PHARMACOLOGY
- Interventions to Promote Physical Activity and Dietary Lifestyle Changes for Cardiovascular Risk Factor Reduction in Adults
- (2010) Nancy T. Artinian et al. CIRCULATION
- Hypertension in children: new trends and challenges
- (2010) Janusz Feber et al. CLINICAL SCIENCE
- The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology
- (2010) Elizabeth I. Martin et al. CLINICS IN LABORATORY MEDICINE
- Insulin, Insulin Resistance, Obesity, and Cancer
- (2010) Emily Jane Gallagher et al. Current Diabetes Reports
- Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown
- (2010) Patricia Reggio CURRENT MEDICINAL CHEMISTRY
- Nonalcoholic fatty liver disease in children
- (2010) Anna Alisi et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- G Protein Coupled Receptors - In Silico Drug Discovery and Design
- (2010) I. Sela et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice
- (2010) T. Jourdan et al. DIABETES
- How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue
- (2010) Jesús Giraldo DRUG DISCOVERY TODAY
- Label-free whole-cell assays: expanding the scope of GPCR screening
- (2010) Clay W Scott et al. DRUG DISCOVERY TODAY
- Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution
- (2010) M Frost et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats
- (2010) Signe Mølhøj et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models
- (2010) Wei Chen et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies
- (2010) Dick C Chan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Well-being of obese individuals: therapeutic perspectives
- (2010) Jean-Philippe Chaput et al. Future Medicinal Chemistry
- The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation
- (2010) Oscar Gomez et al. GLIA
- A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
- (2010) L J Aronne et al. INTERNATIONAL JOURNAL OF OBESITY
- A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
- (2010) J Proietto et al. INTERNATIONAL JOURNAL OF OBESITY
- Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis
- (2010) D O Okorodudu et al. INTERNATIONAL JOURNAL OF OBESITY
- Risk factors for chronic depression — A systematic review
- (2010) Lars Hölzel et al. JOURNAL OF AFFECTIVE DISORDERS
- Interactions between Intracellular Domains as Key Determinants of the Quaternary Structure and Function of Receptor Heteromers
- (2010) Gemma Navarro et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Review: Update on Newer Antihypertensive Medicines and Interventions
- (2010) Katherine C. Wu et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Central and Peripheral Endocannabinoids and Cognate Acylethanolamides in Humans: Association with Race, Adiposity, and Energy Expenditure
- (2010) Reiner Jumpertz et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
- (2010) Mary-Elizabeth Patti JOURNAL OF CLINICAL INVESTIGATION
- Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity
- (2010) Joseph Tam et al. JOURNAL OF CLINICAL INVESTIGATION
- An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity
- (2010) F. D. Christopoulou et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Discovery ofN-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist for the Treatment of Obesity
- (2010) Lin Yan et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Peptide Hemopressin Acts through CB1 Cannabinoid Receptors to Reduce Food Intake in Rats and Mice
- (2010) G. T. Dodd et al. JOURNAL OF NEUROSCIENCE
- Alterations in the Hippocampal Endocannabinoid System in Diet-Induced Obese Mice
- (2010) F. Massa et al. JOURNAL OF NEUROSCIENCE
- A Selective Cannabinoid-1 Receptor Antagonist, PF-95453, Reduces Body Weight and Body Fat to a Greater Extent than Pair-Fed Controls in Obese Monkeys
- (2010) J. D. Wagner et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor–receptor interactions
- (2010) Kjell Fuxe et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- The Metabolic Syndrome and Cardiovascular Risk
- (2010) Salvatore Mottillo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rimonabant: obituary for a wonder drug
- (2010) S Matthijs Boekholdt et al. LANCET
- Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
- (2010) Eric J Topol et al. LANCET
- Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity
- (2010) Daniel Antonio de Luis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Genome-wide Expression Profiling Revealed Peripheral Effects of Cannabinoid Receptor 1 Inverse Agonists in Improving Insulin Sensitivity and Metabolic Parameters
- (2010) W. Zhao et al. MOLECULAR PHARMACOLOGY
- Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor
- (2010) Michael P. Bokoch et al. NATURE
- Taranabant no longer developed as an antiobesity agent
- (2010) Linda Koch Nature Reviews Endocrinology
- Pharmacological management of appetite expression in obesity
- (2010) Jason C. G. Halford et al. Nature Reviews Endocrinology
- Depression-like phenotype following chronic CB1 receptor antagonism
- (2010) Chad E. Beyer et al. NEUROBIOLOGY OF DISEASE
- Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice
- (2010) M. A. Storr et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists
- (2010) Srinivas Gullapalli et al. NEUROPHARMACOLOGY
- Structure-based drug discovery and protein targets in the CNS
- (2010) Roderick E. Hubbard NEUROPHARMACOLOGY
- Drug Management of Obesity — Efficacy versus Safety
- (2010) Arne Astrup NEW ENGLAND JOURNAL OF MEDICINE
- Navigating the Choices for Diabetes Prevention
- (2010) David M. Nathan NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the Cannabinoid Receptor-1 Antagonist Rimonabant on Inflammation in Mice With Diet-Induced Obesity
- (2010) Qun Wang et al. Obesity
- A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low-Calorie Diet
- (2010) Thomas A. Wadden et al. Obesity
- Oleoylethanolamide affects food intake and sleep–waking cycle through a hypothalamic modulation
- (2010) E. Soria-Gómez et al. PHARMACOLOGICAL RESEARCH
- Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities
- (2010) Yinchiu Lin et al. PHARMACOLOGICAL RESEARCH
- Cannabinoids and the gut: New developments and emerging concepts
- (2010) Angelo A. Izzo et al. PHARMACOLOGY & THERAPEUTICS
- Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas
- (2010) Chen Li et al. PHARMACOLOGY & THERAPEUTICS
- Energy regulatory signals and food reward
- (2010) Dianne P. Figlewicz et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats
- (2010) K.S. Sink et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior
- (2010) P.A. Randall et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat
- (2010) Nina L. Cluny et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression
- (2010) Richard C. Shelton et al. PROGRESS IN NEUROBIOLOGY
- Randomized, controlled, double-blind trial of taranabant for smoking cessation
- (2010) Mary F. Morrison et al. PSYCHOPHARMACOLOGY
- Cannabis Use and Obesity and Young Adults
- (2010) Mohammad R. Hayatbakhsh et al. AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
- Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs
- (2009) Joyce M. Richey et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Modulation of anxiety by acute blockade and genetic deletion of the CB1 cannabinoid receptor in mice together with biogenic amine changes in the forebrain
- (2009) Gunnar Thiemann et al. BEHAVIOURAL BRAIN RESEARCH
- Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission
- (2009) Eva Mikics et al. BEHAVIOURAL PHARMACOLOGY
- The role of the endocannabinoid system in lipogenesis and fatty acid metabolism
- (2009) Roberto Vettor et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
- (2009) Fabrício A. Moreira et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- The brain endocannabinoid system in the regulation of energy balance
- (2009) Denis Richard et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders
- (2009) André J. Scheen et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Intestinal and anorectal motility and functional disorders
- (2009) Jutta Keller et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Novel thioamide derivatives as neutral CB1 receptor antagonists
- (2009) Jonas Boström et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists
- (2009) Martin Cooper et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood–brain-barrier
- (2009) Jean-Marie Receveur et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
- (2009) David J. Heal et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice
- (2009) Gernot Riedel et al. BRITISH JOURNAL OF PHARMACOLOGY
- Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding
- (2009) Angelo A Izzo et al. BRITISH JOURNAL OF PHARMACOLOGY
- From endocannabinoid profiling to ‘endocannabinoid therapeutics’
- (2009) Alessia Ligresti et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Inhibitors of cannabinoid receptors and glucose metabolism
- (2009) André J Scheen et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
- (2009) Hyeon-Kyu Lee et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial
- (2009) P. A. Hollander et al. DIABETES CARE
- A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
- (2009) M. S. Kipnes et al. DIABETES OBESITY & METABOLISM
- Diabesity: therapeutic options
- (2009) S. Colagiuri DIABETES OBESITY & METABOLISM
- Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents
- (2009) A. B. Hauber et al. DIABETIC MEDICINE
- Reduced cannabinoid receptor 1 protein in subcutaneous adipose tissue of obese
- (2009) M. F. Bennetzen et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142
- (2009) K.S. Sink et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis
- (2009) David R Janero et al. EXPERT OPINION ON EMERGING DRUGS
- FAAH deficiency promotes energy storage and enhances the motivation for food
- (2009) C Touriño et al. INTERNATIONAL JOURNAL OF OBESITY
- Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions
- (2009) T M Fong et al. INTERNATIONAL JOURNAL OF OBESITY
- Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control
- (2009) M-H Son et al. INTERNATIONAL JOURNAL OF OBESITY
- The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation
- (2009) V Di Marzo et al. INTERNATIONAL JOURNAL OF OBESITY
- The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis
- (2009) G Gariepy et al. INTERNATIONAL JOURNAL OF OBESITY
- An Overview of Practical Approaches for Handling Missing Data in Clinical Trials
- (2009) Cynthia M. DeSouza et al. Journal of Biopharmaceutical Statistics
- Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results
- (2009) Luis M Ruilope et al. JOURNAL OF HYPERTENSION
- Signal transduction of the CB1 cannabinoid receptor
- (2009) Gábor Turu et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- In vivo, in vitro and in silico methods for small molecule transfer across the BBB
- (2009) Jurgen Mensch et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- The Relative Potency of Inverse Opioid Agonists and a Neutral Opioid Antagonist in Precipitated Withdrawal and Antagonism of Analgesia and Toxicity
- (2009) S. Sirohi et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus
- (2009) Gerhild Becker et al. LANCET
- Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans
- (2009) Marica Bordicchia et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The Critical Role of the Endocannabinoid System in Emotional Homeostasis: Avoiding Excess and Deficiencies
- (2009) E. Marco et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- The structure and function of G-protein-coupled receptors
- (2009) Daniel M. Rosenbaum et al. NATURE
- CB1 antagonists for obesity—what lessons have we learned from rimonabant?
- (2009) Vincenzo Di Marzo et al. Nature Reviews Endocrinology
- The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice
- (2009) n. l. cluny et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Depolarization-induced release of endocannabinoids by murine dorsal motor nucleus of the vagus nerve neurons differentially regulates inhibitory and excitatory neurotransmission
- (2009) Julien Roux et al. NEUROPHARMACOLOGY
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
- (2009) Sagnik Bhattacharyya et al. NEUROPSYCHOPHARMACOLOGY
- CNR1 Gene is Associated with High Neuroticism and Low Agreeableness and Interacts with Recent Negative Life Events to Predict Current Depressive Symptoms
- (2009) Gabriella Juhasz et al. NEUROPSYCHOPHARMACOLOGY
- Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus
- (2009) Seungjoo Lee et al. NEUROSCIENCE LETTERS
- Anandamide Increases the Differentiation of Rat Adipocytes and Causes PPARγ and CB1 Receptor Upregulation
- (2009) Sevasti Karaliota et al. Obesity
- The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets
- (2009) Lisa Getty-Kaushik et al. Obesity
- Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism
- (2009) Daniela Cota et al. Obesity
- Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis
- (2009) A. N. Fabricatore et al. Obesity Reviews
- Use of psychotropic drugs and analgesics among users of antiobesity drugs-a population based study
- (2009) Merethe Omdal Amundsen et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation
- (2009) Vincenzo Di Marzo PHARMACOLOGICAL RESEARCH
- Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats
- (2009) K. S. Sink et al. PSYCHOPHARMACOLOGY
- Sustained Weight Loss After Roux-en-Y Gastric Bypass Is Characterized by Down Regulation of Endocannabinoids and Mitochondrial Function
- (2008) Ana Guijarro et al. ANNALS OF SURGERY
- Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat
- (2008) Jean-Pierre Després et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats
- (2008) Janel Hodge et al. BEHAVIOURAL BRAIN RESEARCH
- Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice
- (2008) Jesse LoVerme et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake
- (2008) Carol Addy et al. Cell Metabolism
- Enzymatic Pathways That Regulate Endocannabinoid Signaling in the Nervous System
- (2008) Kay Ahn et al. CHEMICAL REVIEWS
- Blood–brain barrier permeability considerations for CNS-targeted compound library design
- (2008) Stephen A Hitchcock CURRENT OPINION IN CHEMICAL BIOLOGY
- The Role of Adipocyte Insulin Resistance in the Pathogenesis of Obesity-Related Elevations in Endocannabinoids
- (2008) T. M. D'Eon et al. DIABETES
- Peripheral, but Not Central, CB1 Antagonism Provides Food Intake-Independent Metabolic Benefits in Diet-Induced Obese Rats
- (2008) R. Nogueiras et al. DIABETES
- SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES CARE
- Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program
- (2008) L. Van Gaal et al. DIABETES CARE
- Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors
- (2008) V. Di Marzo et al. DIABETOLOGIA
- Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle
- (2008) K. Eckardt et al. DIABETOLOGIA
- Increased Energy Expenditure Contributes More to the Body Weight-Reducing Effect of Rimonabant than Reduced Food Intake in Candy-Fed Wistar Rats
- (2008) Andreas W. Herling et al. ENDOCRINOLOGY
- The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS
- (2008) U. Kintscher EUROPEAN HEART JOURNAL
- Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †
- (2008) Luc F. Van Gaal et al. EUROPEAN HEART JOURNAL
- Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor
- (2008) Richard Z. Chen et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Hope and Fear of Rimonabant
- (2008) John S. Rumsfeld JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors
- (2008) Meritxell Canals et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice
- (2008) Douglas Osei-Hyiaman et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Health
- (2008) Carol Addy et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Bioisosteric Replacement of the Pyrazole 5-Aryl Moiety ofN-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A Novel Series of Alkynylthiophenes as Potent and Selective Cannabinoid-1 Receptor Antagonists
- (2008) Shi-Liang Tseng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist
- (2008) David A. Griffith et al. JOURNAL OF MEDICINAL CHEMISTRY
- Central Versus Peripheral Antagonism of Cannabinoid CB1 Receptor in Obesity: Effects of LH-21, a Peripherally Acting Neutral Cannabinoid Receptor Antagonist, in Zucker Rats
- (2008) F. J. Pavón et al. JOURNAL OF NEUROENDOCRINOLOGY
- CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant
- (2008) A. J. Scheen JOURNAL OF NEUROENDOCRINOLOGY
- Dysregulation of the Endocannabinoid System in Obesity
- (2008) S. Engeli JOURNAL OF NEUROENDOCRINOLOGY
- Cannabinoid Receptors: Where They are and What They do
- (2008) K. Mackie JOURNAL OF NEUROENDOCRINOLOGY
- Activating Parabrachial Cannabinoid CB1 Receptors Selectively Stimulates Feeding of Palatable Foods in Rats
- (2008) N. V. DiPatrizio et al. JOURNAL OF NEUROSCIENCE
- Genetic variation may influence obesity only under conditions of diet: Analysis of three candidate genes
- (2008) Jens Aberle et al. MOLECULAR GENETICS AND METABOLISM
- The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase
- (2008) I. Esposito et al. MOLECULAR PHARMACOLOGY
- Leptin controls adipose tissue lipogenesis via central, STAT3–independent mechanisms
- (2008) Christoph Buettner et al. NATURE MEDICINE
- End of the line for cannabinoid receptor 1 as an anti-obesity target?
- (2008) Dan Jones NATURE REVIEWS DRUG DISCOVERY
- Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet
- (2008) Katarzyna M. Starowicz et al. Obesity
- Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanisms of activation and therapeutics
- (2008) Y TAO PHARMACOLOGY & THERAPEUTICS
- Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats
- (2008) T JARBE et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: Effects on food-reinforced behavior and comparisons with AM4113
- (2008) K.S. Sink et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- The Orexigenic Effect of Ghrelin Is Mediated through Central Activation of the Endogenous Cannabinoid System
- (2008) Blerina Kola et al. PLoS One
- Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses
- (2008) Michel A. Steiner et al. PSYCHONEUROENDOCRINOLOGY
- Why is the neurobiology of nausea and vomiting so important?
- (2007) Charles C. Horn APPETITE
- PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats
- (2007) J G Horswill et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus
- (2007) E Soria-Gómez et al. BRITISH JOURNAL OF PHARMACOLOGY
- Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling
- (2007) Tanya L. Daigle et al. NEUROPHARMACOLOGY
- Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties
- (2007) Jack Bergman et al. PHYSIOLOGY & BEHAVIOR
- Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors
- (2007) Masanori Nakata et al. REGULATORY PEPTIDES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now